TY - JOUR T1 - The efficacy of immune checkpoint inhibitors in thoracic malignancies JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW DO - 10.1183/16000617.0387-2020 VL - 30 IS - 162 SP - 200387 AU - Jordi Remon AU - Francesco Facchinetti AU - Benjamin Besse Y1 - 2021/12/31 UR - http://err.ersjournals.com/content/30/162/200387.abstract N2 - The advent of immune checkpoint inhibitors (ICIs) has rapidly transformed the treatment paradigm for multiple cancer types, including thoracic malignancies. In advanced non-small cell lung cancer (NSCLC), ICIs have shifted treatment paradigm and improved overall survival reaching almost one-third of patients alive at 5 years. ICIs therapies have also modified the therapeutic strategy in first-line setting in metastatic small-cell lung cancer (SCLC) patients as well as in malignant pleural mesothelioma (MPM) improving the overall survival compared with standard treatment. This phenomenon is of huge relevance as both SCLC and MPM were considered orphan diseases without any significant improvement in the therapeutic strategy in the first-line setting during the last 15 years. In this review, we aim to review the efficacy of ICI in thoracic malignancies either in monotherapy or in combination, according to predictive biomarkers, and to the US Food and Drug Administration and the European Medicines Agency approvals of treatment strategies. We address the efficacy of these agents, especially in NSCLC according to PD-L1 expression and histologic subtype.Immunotherapy has shifted the treatment paradigm and improved overall survival in non-small cell lung cancer, small-cell lung cancer and malignant pleural mesothelioma https://bit.ly/3dPg31d ER -